Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer.

Tanaka, N; Miyajima, A; Kosaka, T; Miyazaki, Y; Shirotake, S; Shirakawa, H; Kikuchi, E; Oya, M

Tanaka, N; Miyajima, A; Kosaka, T; Miyazaki, Y; Shirotake, S; Shirakawa, H; Kikuchi, E; Oya, M.

Affiliation

Tanaka N; Department of Urology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.

Br J Cancer ; 105(9): 1331-7, 2011 Oct 25.

Article in En | MEDLINE | ID: mdl-21970881

Subject(s)

Cisplatin/pharmacology; Neovascularization, Pathologic; Receptor, Angiotensin, Type 1/biosynthesis; Urinary Bladder Neoplasms/blood supply; Urinary Bladder Neoplasms/metabolism; Angiotensin II/pharmacology; Angiotensin II Type 1 Receptor Blockers/pharmacology; Animals; Antipyrine/analogs & derivatives; Antipyrine/pharmacology; Cell Line, Tumor; Drug Resistance, Neoplasm; Edaravone; Humans; Mice; Mice, Nude; Reactive Oxygen Species/metabolism; Urinary Bladder Neoplasms/drug therapy; Vascular Endothelial Growth Factor A/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Cisplatin / Receptor, Angiotensin, Type 1 / Neovascularization, Pathologic Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Br J Cancer Year: 2011 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google